• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Bicycle Therapeutics plc

    10/30/25 4:29:25 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCYC alert in real time by email
    S-8 1 tm2529594d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on October 30, 2025.

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 

     

    Bicycle Therapeutics plc 

    (Exact name of registrant as specified in its charter)

     

    England and Wales

    (State or other jurisdiction of
    incorporation or organization)

     

    Not applicable

    (I.R.S. Employer
    Identification No.)

    Blocks A & B, Portway Building

    Granta Park Great Abington, Cambridge

    United Kingdom

    (Address of Principal Executive Offices)

    CB21 6GS

    (Zip Code)

     

    Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan 

    (Full title of the plan)

     

    Alethia Young 

    Chief Financial Officer 

    Bicycle Therapeutics Inc. 

    35 Cambridgepark Drive, Suite 350 

    Cambridge, MA 02140 

    (Name and address of agent for service)

     

    (617) 945-8155 

    (Telephone number, including area code, of agent for service)

     

    Copy to:

     

    Laura A. Berezin 

    Jaime L. Chase 

    Cooley LLP 

    1700 7th Avenue 

    Seattle, WA 98101

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E of Form S-8, Bicycle Therapeutics plc (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an additional 1,300,000 ordinary shares, nominal value £0.01 per share (the “Ordinary Shares”), of the Registrant under the Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan (the “2020 Plan”), pursuant to Amendment No. 1 to the 2020 Plan, which authorizes an additional 1,300,000 shares for issuance under the 2020 Plan. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated herein by reference:

     

    (a)           the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on August 5, 2020 (File No. 333-240993), March 11, 2021 (File No. 333-254163), March 1, 2022 (File No. 333-263156), February 28, 2023 (File No. 333-270091), February 20, 2024 (File No. 333-277171), and February 25, 2025 (File No. 333-285197);

     

    (b)           the Registrant’s Annual Report on Form 10-K (File No. 001-38916) for the fiscal year ended December 31, 2024, filed with the Commission on February 25, 2025 (the “Annual Report”);

     

    (c)           the Registrant’s Quarterly Reports on Form 10-Q (File No. 001-38916) for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, filed with the Commission on May 1, 2025, August 8, 2025, and October 30, 2025, respectively;

     

    (d)           the Registrant’s Definitive Proxy Statement (File No. 001-38916) filed with the Commission on April 23, 2025 (excluding those portions that are not incorporated by reference into the Annual Report);

     

    (e)           the Registrant’s Current Reports on Form 8-K (File No. 001-38916) filed with the Commission on January 13, 2025, March 14, 2025, March 27, 2025, June 17, 2025, August 8, 2025, and September 8, 2025 (in each case, except for information contained therein which is furnished rather than filed); and

     

    (f)            the description of the Registrant’s Ordinary Shares and American Depositary Shares contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-38916) filed with the Commission on May 20, 2019, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.6 to the Annual Report.

     

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for documents or information deemed furnished and not filed in accordance with the rules of the Commission. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    1 

     

     

    Item 8.Exhibits.

     

    Exhibit 
    Number

     

    Exhibit Description

         
    3.1   Articles of Association, dated May 16, 2024 (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q (File No. 001-38916) filed with the Commission on August 6, 2024).
    4.1   Form of Deposit Agreement (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-231076), filed with the Commission on May 13, 2019).
    4.2   Form of American Depositary Receipt (included in Exhibit 4.1) (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-231076), filed with the Commission on May 13, 2019).
    5.1   Opinion of Cooley (UK) LLP.
    23.1   Consent of PricewaterhouseCoopers LLP.
    23.3   Consent of Cooley (UK) LLP (included in Exhibit 5.1).
    24.1   Power of Attorney (included on the signature page to this Registration Statement).
    99.1   Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-38916), filed with the Commission on February 28, 2023).
    99.2   Amendment No. 1 to the 2020 Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Commission on August 8, 2025).
    107   Filing Fee Table

     

    2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, United Kingdom, on October 30, 2025.

     

      BICYCLE THERAPEUTICS PLC
         
      Name: /s/ Kevin Lee
        Kevin Lee, Ph.D., MBA 
        Chief Executive Officer

     

    SIGNATURES AND POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Bicycle Therapeutics plc, hereby severally constitute and appoint Kevin Lee and Alethia Young, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Bicycle Therapeutics plc and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities on October 30, 2025.

     

    Name   Title
         
    /s/ Kevin Lee   Chief Executive Officer and Director
    Kevin Lee, Ph.D., MBA   (Principal Executive Officer)
         
    /s/ Alethia Young   Chief Financial Officer
    Alethia Young   (Principal Financial Officer)
         
    /s/ Travis Thompson   Chief Accounting Officer
    Travis Thompson   (Principal Accounting Officer)
         
    /s/ Felix J. Baker   Chairman of the Board and Director
    Felix J. Baker, Ph.D.    
         
    /s/ Janice Bourque   Director
    Janice Bourque, MBA    
         
    /s/ Roger Dansey   Director
    Roger Dansey, M.D.    
         
    /s/ Jose-Carlos Gutiérrez-Ramos   Director
    Jose-Carlos Gutiérrez-Ramos, Ph.D.    

     

    3 

     

     

    Name   Title
         
    /s/ Hervé Hoppenot   Director
    Hervé Hoppenot    
         
    /s/ Alessandro Riva   Director
    Alessandro Riva, MD    
         
    /s/ Stephen Sands   Director
    Stephen Sands, MBA    
         
    /s/ Charles Swanton   Director
    Charles Swanton, MD, PhD    
         
    /s/ Gregory Winter   Director
    Sir Gregory Winter, FRS    
         
    /s/ Alethia Young   Authorized Representative in the United States
    Alethia Young    

     

    4 

     

    Get the next $BCYC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCYC

    DatePrice TargetRatingAnalyst
    10/31/2025$11.00Outperform → Sector Perform
    RBC Capital Mkts
    11/8/2024$25.00Equal-Weight
    Stephens
    9/6/2024$35.00Outperform
    RBC Capital Mkts
    8/7/2024$33.00 → $28.00Buy → Neutral
    B. Riley Securities
    9/11/2023Neutral → Buy
    B. Riley Securities
    8/31/2022Outperform
    Cowen
    7/28/2022$30.00Overweight
    Barclays
    7/6/2022$60.00Buy
    Canaccord Genuity
    More analyst ratings

    $BCYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bicycle Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Bicycle Therapeutics from Outperform to Sector Perform and set a new price target of $11.00

    10/31/25 8:17:09 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Bicycle Therapeutics with a new price target

    Stephens initiated coverage of Bicycle Therapeutics with a rating of Equal-Weight and set a new price target of $25.00

    11/8/24 7:35:57 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Bicycle Therapeutics with a new price target

    RBC Capital Mkts initiated coverage of Bicycle Therapeutics with a rating of Outperform and set a new price target of $35.00

    9/6/24 7:31:26 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $21,230,385 worth of American Depositary Shares (1,485,397 units at $14.29) (SEC Form 4)

    4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    12/17/24 6:03:39 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Lee Kevin sold $46,182 worth of Ordinary Shares (5,494 units at $8.41), decreasing direct ownership by 1% to 475,310 units (SEC Form 4)

    4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    10/6/25 4:45:16 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF OPERATING OFFICER Milnes Alistair sold $17,860 worth of Ordinary Shares (2,125 units at $8.40), decreasing direct ownership by 2% to 93,377 units (SEC Form 4)

    4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    10/6/25 4:45:13 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguson sold $6,076 worth of Ordinary Shares (723 units at $8.40), decreasing direct ownership by 1% to 53,102 units (SEC Form 4)

    4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    10/6/25 4:45:11 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BCYC
    SEC Filings

    View All

    Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

    Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Enhanced clinical leadership team with appointments to Board of Directors and Research and Innovation Advisory Board Cash and cash equivalents of $648.3 million as of September 30, 2025, excluding $38.2 million U.K. R&D tax credit received in October 2025; expected financial runway into 2028 Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the thi

    10/30/25 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Strengthens Board of Directors with New Appointments

    Roger Dansey, M.D., formerly Pfizer and Seagen, and Hervé Hoppenot, of Incyte and formerly Novartis Oncology, bring extensive drug development and commercialization expertise Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointments of Roger Dansey, M.D., and Hervé Hoppenot to the company's Board of Directors. "We are thrilled to welcome Roger and Hervé to our Board of Directors as we make strong progress across our pipeline and anticipate numerous upcoming milestones. As prominent leaders in oncology research, drug developmen

    9/8/25 4:05:00 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

    Continued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer open and actively recruiting patients Strengthened clinical leadership and bolstered roster of scientific advisors with additions to Board of Directors and creation of Research and Innovation Advisory Board Strategic cost realignment of approximately 30%, primarily through a workforce reduction Cash and cash equivalents of $721.5 million as of June 30, 2025, with expected financial runway extended into 2028 Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pio

    8/8/25 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Bicycle Therapeutics plc

    S-8 - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)

    10/30/25 4:29:25 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Bicycle Therapeutics plc

    10-Q - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)

    10/30/25 7:16:17 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)

    10/30/25 7:05:42 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Leadership Updates

    Live Leadership Updates

    View All

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

    Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025 Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer (NSCLC), resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025 Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025 and first EphA2 human imaging data planned for

    2/25/25 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

    Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company's clinical oncology programs. "We are delighted to welcome Skip, Markus and Niklas to our Clinical Advisory Board. Each of them has dedicated their careers to advancing the care of patients with cancer through the development of novel therapeutics," said Bicycle Therapeutics CEO Kevin Lee, Ph.D. "Their expertise will provide invaluable guidance

    12/10/24 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Financials

    Live finance-specific insights

    View All

    Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

    Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide pevedotin Company to advance development strategy leveraging NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer and multi-tumor planned for 2025 Bicycle Therapeutics to host conference call and webcast with management and

    12/12/24 6:30:00 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

    Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer Conference call and webcast scheduled for Friday, Dec. 13, at 7 a.m. CT to review all data Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the

    11/25/24 5:30:00 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

    First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap

    10/23/24 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

    SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    11/14/24 5:46:12 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

    SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    11/14/24 4:32:50 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care